The 340B program’s growth in recent decades has helped it attract a growing number of corporate and private equity investments, [...] …
Articles by : Shannon Young, Associate Editor/Senior Writer
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
French drugmaker Sanofi has reportedly asked some hospitals for data relating to 340B purchases of a popular drug used to [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
More transparency surrounding 340B hospital operations is needed to ensure drug discount savings are being used to improve patient care, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A federal court last week sided with a group of Texas hospitals’ efforts to block—at least temporarily—a Department of Health [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A major hospital advocacy group recently urged congressional advisers to “carefully consider” the potential negative consequences of any new efforts [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
GlaxoSmithKline (GSK) will refund covered entities that purchased certain formulations of a severe asthma treatment medication in the third quarter [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
340B covered entities could soon be required to share new information—including reimbursement amounts, ship to dates and ship to locations—as [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A former Pfizer executive and current biopharmaceutical consultant took aim this week at what she called the “poorly managed” 340B [...] …